Clinical trial
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed…
NCT00280059 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00280059 |
|---|---|
| Title | Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy |
| Official title | A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy, Partial |
| Intervention type | Drug |
| Interventions | Pregabalin, Lamotrigine |
| Enrollment | 660 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Apr 1, 2010 |
| First posted | Jan 20, 2006 |
| Last update posted | Jan 28, 2021 |
| Countries | Belgium, Bulgaria, China, Colombia, Czechia, Estonia, Finland, France, Germany, Hong Kong, Hungary, India and 17 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: